Latest Conference Articles

Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.

Mark Gibbons of Caregiver Action Network discusses the emotions caregivers to patients with ovarian cancer may have.

Opening the 20th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M.D., underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research.

Nita Karnik Lee, MD, MPH, of The University of Chicago Medicine, discusses what patients with ovarian cancer should know about when entering survivorship.

Mark Gibbons, senior director of external programs with the nonprofit Caregiver Action Network, explains the importance of caregivers taking care of themselves while at the Ovarian Cancer National Conference.

Jennifer Lane-Riefler, MCHES, CFm, Executive Director of Cancer Services of Grant County, discusses the financial assistance opportunities available for patients with ovarian cancer.

Angela Schmidt Fishbaugh talks about being diagnosed with breast cancer after a mastectomy, changing her from a previvor to survivor.

The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and the focus now is on combining PARP inhibitors with other types of therapies.

There are several issues parents should consider before broaching the subject of genetic cancer risk with their children, explains Karen Hurley, a psychologist with the Cleveland Clinic.

Alan Blassberg, Director/Producer of Pink and Blue: Colors of Hereditary Cancer, discusses being a male BRCA carrier.

Sharon Bober, PhD, discusses how patients can ask their doctors about sexual health.

Those considering mastectomy to help prevent inherited breast cancer, or because they’ve been diagnosed with the disease, are likely to find themselves sorting through a host of complex questions.

For women genetically predisposed to ovarian cancer, prevention is extremely important. But what are the most effective and least invasive prevention techniques, and when is the best time in life to employ them?

Knowing that you have an inherited gene mutation can allow you and your family members to look into prevention or detect a cancer at an early stage.

Angela Fishbaugh, author of "Angela's Decision," discusses how to discover your skills and story within.

“This is the first phase 3 study to show an advantage of a PARP inhibitor over standard of care chemotherapy in breast cancer patients with a BRCA mutation,” said principal OLYMPIAD investigator Mark E. Robson, M.D., Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center.

Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.

Sue Friedman, executive director and founder of FORCE, is a hereditary breast cancer survivor herself and has been concentrating on being the support system for others that she didn’t have when she was going through her battle 20 years ago.

The program XRAYS is a resource to help patients, survivors and their loved ones make sense of the articles on hereditary cancer they see in the mainstream media and via social media platforms.

While genetic testing for cancer has some obvious benefits, it also creates ethical dilemmas in many cases.

PolyBalm was effective in mitigating chemotherapy-related nail damage, according to a recent study presented at ASCO.

Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.

When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.

An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.

According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.